Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia

Documenti analoghi

• The Journal in 2023
  di: Jeff Szer
  Pubblicazione: (2024)
• Two decades at the helm: it only seems like a few weeks
  di: Jeff Szer
  Pubblicazione: (2025)
• The Journal in 2024
  di: Jeff Szer
  Pubblicazione: (2025)
• Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era
  di: Diva Baggio, et al.
  Pubblicazione: (2024)
• How should journals respond to the emerging challenges of artificial intelligence?
  di: Paul Komesaroff, et al.
  Pubblicazione: (2024)